Current Progress and Future Opportunities in Liquid Biopsy for Cancer Detection.

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Cancer remains a leading global cause of death, with limited early screening options.
• Early cancer diagnosis significantly improves patient survival, quality of life, and reduces treatment costs.
• Liquid biopsy offers a minimally invasive approach for cancer detection.

Purpose of the Study:

• To review the current landscape of liquid biopsy technologies for cancer detection.
• To evaluate analytical techniques for detecting circulating tumor biomarkers.
• To identify limitations and propose advancements for liquid biopsy applications.

Main Methods:

• Comprehensive analysis of liquid biopsy technologies.
• Evaluation of techniques for detecting Circulating Tumor Cells (CTCs), cell-free DNA (cfDNA), non-coding RNAs (ncRNA), and extracellular vesicles.
• Assessment of biomarker assay sensitivity and specificity.

Main Results:

• Liquid biopsies facilitate molecular characterization for diagnosis, treatment classification, and monitoring.
• Current liquid biopsy techniques often lack the sensitivity required for early-stage cancer detection.
• Early-stage detection is critical for effective cancer treatment.

Conclusions:

• Liquid biopsy is a revolutionary tool in oncology but requires technological advancement.
• Addressing limitations in sensitivity and specificity is key to clinical translation.
• Enhanced liquid biopsy assays are essential for effective early cancer screening.